The androgen receptor (AR) remains a key therapeutic target for prostate cancer (PCa), even in castration resistant PCa (CRPC). Current therapies target AR by blocking androgen synthesis or competiti ...SBIR Phase I 2011 Department of Health and Human Services
ARTA BIOSCIENCE, INC.
| 54 ABERDEEN PL
SAINT LOUIS, MO, 63105-2272
|Socially and Economically Disadvantaged:||N|
|Number of Employees:||n/a|